2024
Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib
Robinson N, Canavan M, Zhan P, Udelsman B, Pathak R, Boffa D, Goldberg S. Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib. Clinical Lung Cancer 2024 PMID: 39462746, DOI: 10.1016/j.cllc.2024.09.006.Peer-Reviewed Original ResearchNon-small cell lung cancerEGFR-mutant non-small cell lung cancerFirst-line osimertinibContinuation of osimertinibImmune checkpoint inhibitorsTyrosine kinase inhibitorsCell lung cancerRetrospective cohort studyOverall survivalTreatment regimensLung cancerAdvanced epidermal growth factor receptorAssociated with increased PFSAssociated with superior PFSSecond-line treatment regimenEGFR exon 19 deletionRetrospective cohort study of patientsEGFR tyrosine kinase inhibitorsAssociated with prolonged survivalCohort study of patientsSecond-line treatment regimensExon 19 deletionFirst-line therapyEpidermal growth factor receptorFirst-line treatment
2019
Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.
Leapman M, Presley C, Zhu W, Soulos P, Adelson K, Boffa D, Gross C. Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2019, 37: 9059-9059. DOI: 10.1200/jco.2019.37.15_suppl.9059.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerPD-L1 expression testingFirst-line therapyNon-small cell lung cancerPD-L1 expressionPD-L1 testingCell lung cancerLung cancerFlatiron Health electronic health record-derived databaseElectronic health record-derived databaseCell death ligand 1 (PD-L1) expressionFDA approvalDeath ligand 1 (PD-L1) expressionReal-world practice patternsFirst-line treatmentLigand 1 expressionProportion of patientsMonths of diagnosisReal-world careMultivariable logistic regressionCommunity oncology practicesCompanion diagnostic testingExpression testingIdentifiable driver mutationsLine treatment